De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment
- Eur J Hum Genet. 2019 Jul;27(7):1081-1089. doi: 10.1038/s41431-019-0366-9.
- 1. Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
- 2. GeneDx, Gaithersburg, MD, USA.
- 3. Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
- 4. Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA.
- 5. Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
- 6. Division of Human Genetics, Department of Pediatrics, Individualized Medical Genetics Center, the Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- 7. Center for Medical Genetics, NorthShore University HealthSystem, Evanston, IL, USA.
- 8. Ocular Genomics Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
- 9. Department of Pediatrics, Columbia University Medical Center, New York, NY, USA. [email protected].
- 10. Department of Medicine, Columbia University Medical Center, New York, NY, USA. [email protected].
Hexokinase 1 (HK1) phosphorylates glucose to glucose-6-phosphate, the first rate-limiting step in glycolysis. Homozygous and heterozygous variants in HK1 have been shown to cause autosomal recessive non-spherocytic hemolytic anemia, autosomal recessive Russe type hereditary motor and sensory neuropathy, and autosomal dominant retinitis pigmentosa (adRP). We report seven patients from six unrelated families with a neurodevelopmental disorder associated with developmental delay, intellectual disability, structural brain abnormality, and visual impairments in whom we identified four novel, de novo missense variants in the N-terminal half of HK1. Hexokinase activity in red blood cells of two patients was normal, suggesting that the disease mechanism is not due to loss of Hexokinase enzymatic activity.